Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504216 | 0.81 | CA12 (0.46) | ALDH1A1PLK1PLK3TAS2R14FABP4 | |
| SCHEMBL1002898 | 0.81 | LPAR2 (0.50) | POLBALDH1A1TDP1L3MBTL1FABP4 | |
| Oxalic Acid SCHEMBL20984131 | 0.79 | POLB (0.75) | POLBALDH1A1TDP1L3MBTL1TAS2R14 | |
| Oxalic Acid SCHEMBL20984818 | 0.78 | POLB (0.53) | POLBALDH1A1TDP1L3MBTL1TAS2R14 | |
| SCHEMBL4453238 | 0.78 | PLK1 (0.52) | POLBALDH1A1L3MBTL1PLK1PLK3 | |
| SCHEMBL23908702 | 0.77 | ALDH1A1 (0.51) | ALDH1A1PLK1PLK3TAS2R14FABP4 | |
| SCHEMBL283130 | 0.77 | HSD17B10 (0.41) | ALDH1A1PLK1PLK3TAS2R14FABP4 | |
| SCHEMBL17627527 | 0.77 | CES2 (0.48) | PLK1PLK3MEN1KMT2AGAA | |
| Water SCHEMBL356237 | 0.75 | HSD17B10 (0.41) | ALDH1A1PLK1PLK3TAS2R14FABP4 | |
| Hydrochloric Acid SCHEMBL4454152 | 0.75 | HSD17B10 (0.41) | POLBALDH1A1TDP1L3MBTL1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2019-05-23 | — | — | US | disclosed |
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2019-03-05 | — | — | US | disclosed |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2017-10-26 | — | — | US | disclosed |
| EP-3197897-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046404-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2016-03-31 | — | — | WO | disclosed |
| EP-3000814-A1 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | Domain Therapeutics (FR) | 2016-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | GRM1, GRM2, GRIN1 | POLB 4316/4885ALDH1A1 2693/4885TDP1 2790/4885 |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | POLB 4316/4885ALDH1A1 2693/4885TDP1 2790/4885 |
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | POLB 4264/4885ALDH1A1 2730/4885TDP1 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.